All Updates

All Updates

icon
Filter
Funding
Aptose Biosciences raises USD 4.4 million in private placement to support working capital
Precision Medicine
May 31, 2024
This week:
Funding
Lhyfe receives EUR 11 million grant from Klimatklivet for green hydrogen project in Sweden
Hydrogen Economy
Yesterday
Product updates
XRAI Glass launches AR One glasses at USD 1449 for hearing-impaired individuals
Extended Reality
Yesterday
Funding
VR therapy platform CUREosity raises EUR 3.8 million in funding to expand market presence
Extended Reality
Yesterday
Last week:
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Decentralized Finance (DeFi)
Jun 22, 2024
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Web3 Ecosystem
Jun 22, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Data Infrastructure & Analytics
Jun 21, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Foundation Models
Jun 21, 2024
Partnerships
Product updates
Anthropic releases Claude 3.5 Sonnet, the first model in the 3.5 series
Foundation Models
Jun 21, 2024
Funding
Paramount Planet Product raises USD 1 million in federal grant funding to support commercialization
Bio-based Materials
Jun 21, 2024
Regulation/policy
Apple delays launch of Apple Intelligence features in EU citing regulatory concerns
Generative AI Applications
Jun 21, 2024
Precision Medicine

Precision Medicine

May 31, 2024

Aptose Biosciences raises USD 4.4 million in private placement to support working capital

Funding

  • Aptose Biosciences has announced private placement funding to raise ~USD 4.4 million. The transaction involves the sale of ~3.9 million of its common shares at USD 1.15 per share. In a concurrent private placement, the company has also decided to issue Series A warrants and Series B warrants, each for purchasing up to ~3.9 million common shares at an exercise price of USD 1.15 per share. H.C. Wainwright & Co. is the exclusive placement agent of the funding round, which is expected to be closed on June 3, 2024.

  • The company aims to use the net proceeds obtained from this offering for general corporate purposes and to supplement its working capital.

  • Aptose Biosciences is a biotechnology company specializing in developing novel therapies for hematologic malignancies. The company’s lead drug candidates include tuspetinib, an oral kinase inhibitor targeting key kinases involved in myeloid malignancies, and luxeptinib, which targets relapsed or refractory B-cell and myeloid malignancies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.